New drug leads for cholesterol

新药降低胆固醇水平

• 批准号: nhmrc : 1107403
• 负责人: Dr Conan Wang
• 金额: $ 42.51万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/new-drug-leads-cholesterol/662979
• 关键词: New; drug; leads; cholesterol

We aim to develop a new class of cholesterol-lowering drugs by blocking the interaction between a protein in the blood called PCSK9 and its receptor, which is implicated in cholesterol absorption. We will do this by designing small stable peptides (mini proteins) that mimic part of the receptor and have the potential to interfere with the normal PCSK9 binding process. These drugs should be less expensive and potentially less immunogenic than competing therapies based on antibodies.

我们的目标是通过阻断血液中一种名为PCSK 9的蛋白质与其受体之间的相互作用来开发一类新型降胆固醇药物，该蛋白质与胆固醇吸收有关。我们将通过设计小的稳定肽（迷你蛋白）来做到这一点，这些肽模拟受体的一部分，并有可能干扰正常的PCSK 9结合过程。与基于抗体的竞争疗法相比，这些药物应该更便宜，免疫原性更低。